Medicine
Skyrizi kit
Skyrizi kit is a prescription medicine containing Risankizumab for intravenous use, marketed by AbbVie, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians. It ships in a temperature-controlled cold chain.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Cold chain
Store in a refrigerator at 36°F to 46° F (2°C to 8°C). Do not freeze. Do not…
Key facts
- Active ingredient (INN)
- Risankizumab
- Brand
- Skyrizi
- Dosage form
- Kit
- Route
- Intravenous
- Packs
- 1 kit
- Marketing authorisation holder
- AbbVie
- Manufacturer
- AbbVie
- Origin register
- US FDA, United States
- Storage
- Store in a refrigerator at 36°F to 46° F (2°C to 8°C). Do not freeze. Do not shake. Keep in the original cartons to protect from light.
- Cold chain
- Yes, shipped temperature controlled
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- L04AC18 Risankizumab
- HS code (indicative)
- 3002.15Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 16 June 2022
- Identifiers
- RxCUI 2540692, 2540695, 2540698 +7DailyMed set ID 7148c8eb-b39e-e20a-6494-a6df82392858NDC 0074-1084, 0074-1070, 0074-1065Application BLA761105
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 kit in 1 carton * 1.2 mL in 1 cartridge * 1.2 mL in 1 cartridge | 0074-1065-01 | AbbVie | 23 September 2022 |
| 1 kit in 1 carton * 2.4 mL in 1 cartridge * 2.4 mL in 1 cartridge | 0074-1070-01 | AbbVie | 16 June 2022 |
| 1 kit in 1 carton * 2 cartridge in 1 carton / 2.4 mL in 1 cartridge * 1 mL in 1 packet | 0074-1084-01 | AbbVie | 26 October 2026 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Alternatives
Other makers and brands of Risankizumab kit.
Other strengths and forms of Risankizumab
Clinical summary
Risankizumab is an interleukin-23 antagonist indicated for the treatment of moderate-to-severe plaque psoriasis in adults and pediatric patients 6 years of age and older who are candidates for systemic therapy or phototherapy, among other approved uses. MedsAcross supplies Risankizumab for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about RisankizumabFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Skyrizi prescribing information (AbbVie) · U.S. National Library of Medicine, DailyMed
- Skyrizi: European public assessment report (EPAR) · European Medicines Agency
Need Skyrizi kit for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.